Genmab reports Phase 3 trial shows 71% reduction in disease progression for ovarian cancer drug Rina‑S
Genmab announced that its Phase 3 RAINFOL‑02 trial of the antibody‑drug conjugate Rina‑S met its primary endpoint of progression‑free survival and the key secondary endpoint of overall survival in patients with platinum‑resistant ovarian cancer. In the intent‑to‑treat population the drug cut the risk of disease progression or death by 71% (hazard ratio 0.29). The company said it will discuss the data with regulators worldwide and will present the results at a future medical meeting.
Why it matters
The trial outcome de‑risked Genmab’s pipeline and triggered a sharp share price increase, with the stock up 6.8%‑9% on the day of the announcement. Analysts raised price targets, including Guggenheim’s new $54 target.
Key facts
- 1The intent‑to‑treat (ITT) population included 584 randomized patients. gurufocus.com
- 2In the ITT group, Rina‑S reduced the risk of disease progression or death by 71% (HR 0.29). gurufocus.com
- 3In the primary analysis set (PAS) of 492 patients, the risk reduction was 67% (HR 0.33). gurufocus.com
- 4Overall survival improved with a hazard ratio of 0.43 in the ITT population. gurufocus.com
- 5Genmab’s stock rose 6.8% in mid‑day trading after the release. investing.com
- 6Another report noted a 9% share price jump following the results. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.